Assessment of cardiac involvement in rare forms of amyloidosis using positron emission tomography/computed tomography with 124I-evuzamitide (124I-p5+14, AT-01)
Top Cited Papers
- 3 April 2026
- journal article
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 60, 102707
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- Ionis Pharmaceuticals
- Novo Nordisk
This publication has 22 references indexed in Scilit:
- Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed TomographyJACC: Cardiovascular Imaging, 2025
- Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain AmyloidosisJACC: Cardiovascular Imaging, 2024
- Cardiac Amyloidosis Due to Transthyretin ProteinJAMA, 2024
- Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14)JACC: Cardiovascular Imaging, 2023
- Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-FlorbetapirJACC: Cardiovascular Imaging, 2023
- In the thick of it: hereditary cardiac amyloidosis identified by 124I-AT-01 PET imaging but not cardiac MRI or SPECT 99mTc pyrophosphate scintigraphyJournal of Nuclear Cardiology, 2023
- First in Human Evaluation and Dosimetry Calculations for Peptide 124I-p5+14—a Novel Radiotracer for the Detection of Systemic Amyloidosis Using PET/CT ImagingMolecular Imaging and Biology, 2021
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2—evidence base and standardized methods of imagingJournal of Nuclear Cardiology, 2019
- Myocardial tissue characterization in patients with hereditary gelsolin (AGel) amyloidosis using novel cardiovascular magnetic resonance techniquesThe International Journal of Cardiovascular Imaging, 2019
- Tc-99m Radiolabeled Peptide p5 + 14 is an Effective Probe for SPECT Imaging of Systemic AmyloidosisMolecular Imaging and Biology, 2015